Patient Reported Outcomes in Pulmonary Arterial Hypertension

Back to Search
Print
Bookmark Trial

NCT01792622

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of a personally signed and dated informed consent

- Subjects aged >=18 who have documented PAH

- Speak English

- Subjects who provide written informed consent to participate in the study before being screened for the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with non-PAH Pulmonary Hypertension


- Physical inability to complete the interview process


- Subjects who are currently enrolled in an experimental drug study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pulmonary Arterial HypertensionPatient Reported Outcomes in Pulmonary Arterial Hypertension
NCT01792622
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionAssess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
NCT00323297
  1. Los Angeles, California
  2. Detroit, Michigan
  3. Pittsburgh, Pennsylvania
  4. Houston, Texas
  5. Houston, Texas
  6. San Antonio, Texas
  7. Darlinghurst, New South Wales
  8. Chermside, Queensland
  9. Praha 2,
  10. Praha 4,
  11. Lille,
  12. Lille,
  13. Vandoeuvre Les Nancy,
  14. Berlin,
  15. Coburg,
  16. Essen,
  17. Giessen,
  18. Hannover,
  19. Homburg,
  20. Leipzig,
  21. Muenchen,
  22. Nuernberg,
  23. Wuerzburg,
  24. Haidari, Athens
  25. Haifa,
  26. Petach Tikva,
  27. Napoli,
  28. Roma,
  29. Taipei,
  30. Papworth Everard, Cambridgeshire
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionOpen Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
NCT00878943
  1. Hyderabad, Andra Pradesh
  2. Ahmedabad, Gujarat
  3. Vadodara, Gujarat
  4. Bangalore, Karnataka
  5. Noida, Uttar Pradesh
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionTo Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
NCT00430716
  1. Phoenix, Arizona
  2. Augusta, Georgia
  3. Decatur, Georgia
  4. Elk Grove Village, Illinois
  5. Indianapolis, Indiana
  6. Chapel Hill, North Carolina
  7. Charlotte, North Carolina
  8. Charlotte, North Carolina
  9. Houston, Texas
  10. Houston, Texas
  11. Salt Lake City, Utah
  12. Richmond, Virginia
  13. Richmond, Virginia
  14. Richmond, Virginia
  15. Richmond, Virginia
  16. Leuven,
  17. Porto Alegre, RS
  18. Sao Paulo, SP
  19. Sofia,
  20. Sofia,
  21. Beijing,
  22. Shanghai,
  23. Haidari, Athens
  24. Hyderabad, Andhra Pradesh
  25. Ahmedabad, Gujarat
  26. Vadodara, Gujarat
  27. Bangalore, Karnataka
  28. Noida, Uttar Pradesh
  29. Pavia,
  30. Roma,
  31. Riga,
  32. Kuala Lumpur,
  33. Amsterdam,
  34. Rotterdam,
  35. Manila City,
  36. Quezon City,
  37. Krakow,
  38. Zabrze,
  39. Timisoara, Timis
  40. Iasi,
  41. Moscow,
  42. Moscow,
  43. Amphoe Mueang, Khon Kaen
  44. Bangkok,
  45. Norwich, Norfolk
  46. Newcastle Upon Tyne, Tyne and Wear
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Patient Reported Outcomes in Pulmonary Arterial Hypertension
Official Title Patient Reported Outcomes in Pulmonary Arterial Hypertension
Brief Summary Develop a brief, new, patient reported outcome instrument that is valid for use in clinical practice and clinical trials.
Detailed Description This study will use the Clinical Impact Method to develop a patient reported outcome for use in patients with pulmonary arterial hypertension Clinical personnel at the study sites will approach and discuss possible participation in Phase I and II of the study with subjects from the existing pool of patients currently receiving usual and customary care at the site.
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients with pulmonary arterial hypertension
Condition Pulmonary Arterial Hypertension
Intervention
  • Other: Interview
    Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
  • Other: Questionnaire
    Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
Study Groups/Cohorts
  • Phase I Patient Interviews
    Indepth interviews will be completed with approximately 15 patients.
    Intervention: Other: Interview
  • Phase II Patient Questionnaire
    Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
    Intervention: Other: Questionnaire
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: July 31, 2013)		0
Original Estimated Enrollment
 (submitted: February 13, 2013)		220
Estimated Study Completion Date September 2013
Estimated Primary Completion Date September 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent
  • Subjects aged >=18 who have documented PAH
  • Speak English
  • Subjects who provide written informed consent to participate in the study before being screened for the study.

Exclusion Criteria:

  • Patients with non-PAH Pulmonary Hypertension
  • Physical inability to complete the interview process
  • Subjects who are currently enrolled in an experimental drug study
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years to 100 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01792622
Other Study ID Numbers A1481296
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators
  • University of Chicago
  • Mayo Clinic
  • Vanderbilt University
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021